There is an increasing need to move diagnostic testing to point-of-care (POC) facilities and applications, especially for rapid-onset cardiac conditions such as congestive heart failure (CHF) and myocardial infarction (MI). The Centers for Disease Control and American Heart Association reported that annually, over 5.7 million adults suffer from CHF or MI, incurring costs over $50 billion. Symptoms of these conditions such as breathlessness or chest pain are misdiagnosed is about 40 percent of cases, allowing the disease to remain silent until serious complications arise. Although biomarkers could improve accuracy, they are investigated only about 50 percent of the time. To remove the barriers for testing, Cardiosense was designed as a portable device for rapidly and accurately screening patients for CHF and MI biomarkers. Accurate POC testing ensures that the patients receive the most appropriate medical care in a timely and expedient fashion.

Technology Description

CardioSense is a POC handheld biosensor that serves as a preliminary diagnostic and prognostic tool for CHF and MI. Using electrochemical impedance spectroscopy (EIS) and aptamers, CardioSense can detect biomarkers specific to CHF and MI in a cost-effective manner. Use of EIS makes the device highly sensitive, thus allowing the detection of biomarkers within minutes from just a finger prick’s worth of blood, eliminating the need for long turnover and blood processing times required by current biomarker diagnostic techniques. In addition, aptamers improve the sensitivity of the device and allow the device to be reusable, thus reducing the amount of times the electrode disks need to be changed.

Advantages

  • Eliminates the need for processing blood prior to testing
  • Detects concentrations of biomarkers within minutes for rapid diagnosis/prognosis
  • Highly sensitive, allowing for the detection of even trace concentrations of biomarkers
  • Scaled down into a handheld model for ease of use and portability
  • Aptamers and disks can be reused numerous times
  • Cost-effective and inexpensive to make
  • Universal platform for additional applications beyond CHF and MI

Applications

  • Detection of brain natriuretic peptide and troponin T for the diagnosis and screening of CHF and MI
  • Can be branched out to other cardiac markers to detect other cardiovascular diseases (i.e. creatinine kinase, myoglobin) or other disease states (e.g., traumatic brain Injury)
  • Can also be used with antibodies, enzymes, and other biological detection elements, thus reducing the cost of developing new aptamers

IP Status

PCT patent filed on Oct. 4, 2016

Stage of Development

Optimization in the laboratory.

Notable Mentions

  • 2017 Coulter Translation Research Partners II Program Award (Funding: $50,000, November 2017)
  • 2016 Clinical and Translational Science Institute T1/T2 Pilot Award (Funding: $25,000, March 2017)
  • 2016 McGowan Institute of Regenerative Medicine First Place Poster Award, Category: Medical Devices (No Funding)
  • 2015 Michael G. Wells Healthcare Competition Third Place Award (Funding: $3,000 Effective October 2015)